Cost effectiveness of evidence-based treatment guidelines for the treatment of non-small-cell lung cancer in the community setting

Journal of Oncology Practice

Volumn 6, Issue 1, 2010, Pages 12-18

  Neubauer, Marcus A ^a   Hoverman, J Russell ^a   Kolodziej, Michael ^a   Reisman, Lonny ^a   Gruschkus, Stephen K ^a   Hoang, Susan ^a   Alva, Albert A ^a   McArthur, Marilyn ^a   Forsyth, Michael ^a   Rothermel, Todd ^a   Beveridge, Roy A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; EVIDENCE BASED MEDICINE; FEMALE; HEALTH CARE COST; HEALTH CARE DELIVERY; HOSPITALIZATION COST; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE;

EID: 77749289253     PISSN: 15547477     EISSN: None     Source Type: Journal    
DOI: 10.1200/JOP.091058     Document Type: Article

References (23)

1. American Cancer Society: Statistics for 2009: Cancer Facts & Figures 2009. http://www.cancer.org/docroot/STT/STT-0.asp
2. National Cancer Institute: Cancer Trends Progress Report-2007 Update. http://progressreport.cancer.gov
3. Goldstraw P, Crowley J, Chansky K, et al: The IASLC Lung Cancer Staging Project: Proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2:706-714, 2007
4. Piana R: Cancer drug pipeline is healthy, says head of oncologic drug approval for FDA. Oncology News International. http://www.cancernetwork.com/ display/article/10165/1263819?verify=0
5. Kritz FL: Cancer patients facing costly treatments can benefit from frank talks with doctors. Los Angeles Times: February 16, 2009
6. Schiller JH, Harrington D, Belani CP, et al: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92-8, 2002
7. Scagliotti GV, De Marinis F, Rinaldi M, et al: Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 20:4285-4291, 2002
8. Ohe Y, Ohashi Y, Kubota K, et al: Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol 18:317-323, 2007
9. Carlson JJ, Veenstra DL, Ramsey SD: Pharmacoeconomic evaluations in the treatment of non- small cell lung cancer. Drugs 68:1105-1113, 2008
10. Lin DY, Feuer EJ, Etzioni R, et al: Estimating medical costs from incomplete follow-up data. Biometrics 53:419-434, 1997
11. Efron B, Tibshirani RJ: An Introduction to the Bootstrap. Boca Raton, FL, Chapman & Hall, 1993
12. Mitra N, Indurkhya A: A propensity score approach to estimating the cost-effectiveness of medical therapies from observational data. Health Econ 14:805-815, 2005
13. Indurkhya A, Mitra N, Schrag D: Using propensity scores to estimate the cost-effectiveness of medical therapies. Stat Med 25:1561-176, 2006
14. Stinnett AA, Mullahy J: Net health benefits: A new framework for the analysis of uncertainty in costeffectiveness analysis. Med Dec Mak 18:S65-S80, 1998 (suppl 2)
15. van Hout BA, Al MJ, Gordon GS, et al: Costs, effects and C:E-ratios alongside a clinical trial. Health Econ 3:309-319, 1994
16. Willan AR, Lin DY, Manca A: Regression methods for cost-effectiveness analysis with censored data. Stat Med 24:131-145, 2005
17. Fisher ES, Wennberg JE: Health care quality, geographic variations, and the challenge of supply-sensitive care. Perspect Biol Med 46:69-79, 2003
18. Fisher ES, Wennberg DE, Stukel TA, et al: The implications of regional variations in Medicare spending: Part 1-The content, quality, and accessibility of care. Ann Intern Med 138:273-287, 2003
19. Fisher ES, Wennberg DE, Stukel TA, et al: The implications of regional variations in Medicare spending: Part 2-Health outcomes and satisfaction with care. Ann Intern Med 138:288-298, 2003
20. Wennberg JE, Fisher ES, Baker L, et al: Evaluating the efficiency of California providers in caring for patients with chronic illnesses. Health Aff (Millwood). W5: 526-543, 2005 (suppl)
21. Hoverman JR, Robertson SM: Lung cancer: A cost and outcome study based on physician practice patterns. Dis Manag 7:112-123, 2004
22. Coukell AJ, Noble S, Faulds D: Vinorelbine in advanced non-small cell lung cancer: A pharmacoeconomic review. Pharmacoeconomics 15:405-417, 1999
23. Grilli R, Magrini N, Penna A, et al: Practice guidelines developed by specialty societies: The need for a critical appraisal. Lancet 355:103-106, 2000